Skip to main content

Research Repository

Advanced Search

Outputs (2)

Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study (2019)
Journal Article
Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., …Sathyapalan, T. (2019). Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clinical Endocrinology, 90(6), 805-813. https://doi.org/10.1111/cen.13968

Background: Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascu... Read More about Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study.

A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome (2019)
Journal Article
Javed, Z., Papageorgiou, M., Deshmukh, H., Kilpatrick, E., Mann, V., Corless, L., …Sathyapalan, T. (2019). A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome. Nutrients, 11(1), 188. https://doi.org/10.3390/nu11010188

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. Polycystic ovary syndrome (PCOS) increases the risk of metabolic syndrome and non-alcoholic-fatty-liver disease (NAFLD). Vitamin D supplementation may exert positive effects on liver biochemis... Read More about A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome.